FindTrial
Sign In

Phase II/III Clinical Study of R484iv (Ibandronic acid) for Primary Osteoporosis

Phase II/III Clinical Study of R484iv (Ibandronic acid) for Primary Osteoporosis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220364
Enrollment
Unknown
Registered
2007-03-20
Start date
2007-03-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

investigational material(s) Generic name etc : R484iv (Ibandronic acid) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration

Sponsors

Chugai Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Osteoporosis patients with fragile bone fracture, low bone mineral density and vertebral fracture

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Incidence of non-traumatic vertebral fracture (including deterioration of prevalent fracture)—

Contacts

Public Contact; ;

Chugai Pharmaceutical Co., Ltd.;Taisho Pharmaceutical Co., Ltd.

;;

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026